Lenire ®.: Difference between revisions
mNo edit summary |
Isabell8639 (talk | contribs) mNo edit summary |
||
Line 1: | Line 1: | ||
Panakès Allies is an Equity capital firm, based in Milan, which invests in one of the most ambitious companies and teams, creating revolutionary technologies and products, in the field of life sciences, intending to improve the lives of individuals all over the world.<br><br>Founded in 2010 by Dr. Ross 'Neill, CEO, Neuromod Instruments is a clinical modern technology firm that specialises in the layout and advancement of neuromodulation innovations to resolve the clinical requirements of underserved individual populaces that live with devastating and chronic problems.<br><br>Given that the previous round of funding elevated in October 2020, the business has made progress commercialising Lenire, expanding the device's availability throughout Europe, establishing an entirely possessed US subsidiary, [https://atavi.com/share/wp3bfjz8gdfk neuromod devices wirbt 30 millionen euro ein] U.S.A. Inc, and securing United States market approval from the FDA. <br><br>The initial of these trials, TENT-A1, represents one of the largest and longest followed-up scientific tests ever performed in the ringing in the ears field and was the cover tale for the clinical journal Science Translational Medicine in October 2020. |
Revision as of 14:19, 15 June 2024
Panakès Allies is an Equity capital firm, based in Milan, which invests in one of the most ambitious companies and teams, creating revolutionary technologies and products, in the field of life sciences, intending to improve the lives of individuals all over the world.
Founded in 2010 by Dr. Ross 'Neill, CEO, Neuromod Instruments is a clinical modern technology firm that specialises in the layout and advancement of neuromodulation innovations to resolve the clinical requirements of underserved individual populaces that live with devastating and chronic problems.
Given that the previous round of funding elevated in October 2020, the business has made progress commercialising Lenire, expanding the device's availability throughout Europe, establishing an entirely possessed US subsidiary, neuromod devices wirbt 30 millionen euro ein U.S.A. Inc, and securing United States market approval from the FDA.
The initial of these trials, TENT-A1, represents one of the largest and longest followed-up scientific tests ever performed in the ringing in the ears field and was the cover tale for the clinical journal Science Translational Medicine in October 2020.